ADVANCE Retinopathy Measurements (ADREM)

The aim of this sub study is to measure the incidence and progression of background retinopathy by blood pressure lowering or intensive glucose control in patients with type 2 diabetes.

ADVANCE participants from Australia, Canada, China, Estonia, Germany, India, Ireland, Malaysia, Netherlands, Slovakia, and the United Kingdom (UK) were included in this substudy, and had retinal photographs obtained at baseline, two years and at the end of follow-up for the blood pressure arm of the study.